CRANBURY, N.J.--(BUSINESS WIRE)--The Center for Biosimilars®, an online resource for emerging therapies that focuses on improving patient outcomes, launched its latest video interview series featuring Sheila Frame, vice president, head of biopharmaceuticals, North America, Sandoz, a Novartis Division. The interview discusses the evolving pharmaceutical marketplace and the role of Sandoz in the growing field of biosimilars. The first five segments of the 12-part series are available online.
During the interview, Frame said: “If we don’t create the room in the marketplace to take advantage of these savings now, then we are not going to be able to have access to those new innovations. I think that’s what excited us the most at Sandoz, in terms of the value that we can create for Americans, in the U.S. healthcare system.”
Frame also delved into challenges faced by the pharmaceutical industry to launch biosimilars to the market. She highlighted key differences such as the innovation protection policies and patents to protect inventions and compared the U.S. and European markets. The series identifies immunology and oncology as the biggest therapeutic areas for biosimilar needs. Regarding the recognition of biosimilars by professionals, Frame mentioned that clinicians have shown acceptance to better optimize patient outcomes.
To view additional segments from this series and access to other series featuring distinguished professionals in the field of biosimilars, visit http://www.centerforbiosimilars.com/interviews.
About The Center for Biosimilars®
The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Biosimilars®, which was cited in a United States Senate testimony on drug prices and out-of-pocket costs for rheumatoid arthritis drugs, discusses the current landscape for advanced healthcare management.
